Clinical Research Directory

Inclusion Criteria: * Have signed the informed consent form (ICF) as per local regulations * Female or male aged 18 years or older * Ability to comply with the study protocol, in the judgment of the investigator * Life expectancy ≥ 12 weeks * Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2 * Have a confirmed diagnosis of locally advanced or metastatic NSCLC on or after the date of local approval for ALK-TKIs as first-line monotherapy regimen for ALK-positive advanced NSCLC and planned to receive treatment as per routine for at least one cycle (28 days) while on study * ALK positive as determined by Ventana immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), reverse transcription polymerase chain reaction(RT-PCR) and next generation sequencing (NGS), documented prior to receiving treatment with an ALK inhibitor * Planned to receive, treatment for ALK-positive advanced NSCLC with ALK-TKIs * Able to be followed up at the participating site * Patients with advanced NSCLC who have asymptomatic central nervous system (CNS) metastases are eligible for inclusion Exclusion Criteria: * Patients receiving ALK-TKIs as investigational study drugs in a clinical trial for the treatment of advanced NSCLC * Patients participating in clinical trials within 28 days prior to initiation of study treatment * Pregnant, lactating, or breastfeeding women